Ang Shy-Yau, Shih Ching-Yu, Ho Hua, Chen Yen-Lin, Sun Jen-Tang, Cheng Chiao-Yin
Department of Emergency Medicine, Far Eastern Memorial Hospital, New Taipei 220, Taiwan.
Center for Precision Medicine and Genomics, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan.
J Clin Med. 2025 Jul 29;14(15):5360. doi: 10.3390/jcm14155360.
: Eph receptor A5 (EphA5) is a receptor tyrosine kinase that is implicated in multiple malignancies, although its role in endometrial cancer (EC) remains unclear. The aim of this study was to investigate the clinicopathological significance of EphA5 expression in EC and explore its association with proliferative and metabolic markers. : We retrospectively analyzed 75 EC tissue samples from treatment-naïve patients by using immunohistochemistry and H-score quantification. Associations between EphA5 expression and clinicopathological parameters were assessed through logistic regression analysis. Kaplan-Meier analysis was used to evaluate survival outcomes. Correlation analysis, stratified according to cancer stage, was used to explore biomarker interactions. : High EphA5 expression levels were significantly associated with elevated Ki-67 expression (adjusted odds ratio (aOR): 1.08 per 1-point H-score increase, = 0.024) and decreased pAMPK expression (aOR: 0.89 per 1-point H-score increase, = 0.024), indicating its involvement in proliferative and metabolic pathways. Paradoxically, patients with high EphA5 levels had significantly better overall survival probabilities (H-score > 105, log-rank = 0.007). Stage-specific analyses suggested that EphA5 levels correlated with proliferation in early-stage disease and epithelial-mesenchymal transition in advanced stages. : EphA5 may act as a context-dependent biomarker in EC. Despite its positive correlation with proliferation and negative association with metabolic stress signaling, high EphA5 expression levels were predictive of a favorable prognosis.
Eph受体A5（EphA5）是一种受体酪氨酸激酶，与多种恶性肿瘤有关，但其在子宫内膜癌（EC）中的作用仍不清楚。本研究的目的是探讨EphA5在EC中的表达的临床病理意义，并探讨其与增殖和代谢标志物的关系。我们通过免疫组织化学和H评分定量回顾性分析了75例未经治疗的患者的EC组织样本。通过逻辑回归分析评估EphA5表达与临床病理参数之间的关联。采用Kaplan-Meier分析评估生存结果。根据癌症分期进行分层的相关分析用于探索生物标志物之间的相互作用。EphA5高表达水平与Ki-67表达升高（调整优势比（aOR）：H评分每增加1分，为1.08，P = 0.024）和pAMPK表达降低（aOR：H评分每增加1分，为0.89，P = 0.024）显著相关，表明其参与增殖和代谢途径。矛盾的是，EphA5水平高的患者总体生存概率显著更高（H评分>105，对数秩检验P = 0.007）。特定阶段分析表明，EphA5水平与早期疾病的增殖和晚期上皮-间质转化相关。EphA5可能是EC中一种依赖于背景的生物标志物。尽管其与增殖呈正相关且与代谢应激信号呈负相关，但EphA5高表达水平预示着良好的预后。
